CSEP 527 Computational Biology

**Gene Expression Analysis** 

## Assaying Gene Expression







## **Goals of RNAseq**

- #1: Which genes are being expressed? How? assemble reads (fragments of mRNAs) into (nearly) full-length mRNAs and/or map them to a reference genome
- #2: How highly expressed are they?

How? *count* how many fragments come from each gene–expect more highly expressed genes to yield more reads, after correcting for biases like mRNA length

#3: What's same/diff between 2 samples

E.g., tumor/normal

#4: ...

## **Recall: splicing**



## **RNAseq Data Analysis**

De novo Assembly

mostly deBruijn-based, but likely to change with longer reads more complex than genome assembly due to alt splicing, wide diffs in expression levels; e.g. often multiple "k's" used pro: no ref needed (non-model orgs), novel discoveries possible, e.g. very short exons

con: less sensitive to weakly-expressed genes

Reference-based (more later)

pro/con: basically the reverse

Both: subsequent bias correction, quantitation, differential expression calls, fusion detection, etc.

## "TopHat" (Ref based example)

- map reads to ref transcriptome (optional)
- map reads to ref genome

BWA

- unmapped reads remapped as 25mers
- novel splices = 25mers anchored 2 sides
- stitch original reads across these
- remap reads with minimal overlaps
- Roughly: 10m reads/hr, 4Gbytes (typical data set 100m–1b reads)





## RNAseq protocol (approx)

Extract RNA (either polyA ↔ polyT or tot – rRNA) Reverse-transcribe into DNA ("cDNA") Make double-stranded, maybe amplify Cut into, say, ~300bp fragments Add adaptors to each end Sequence ~100-175bp from one or both ends

CAUTIONS: non-uniform sampling, sequence (e.g. G+C), 5'-3', and length biases

Two Stories:

- RNAseq Bias Correction & Isoform
   Quantification
- Let-7 & Cardiomyocyte Maturation

### Walter L. (Larry) Ruzzo

Computer Science and Engineering Genome Sciences University of Washington Fred Hutchinson Cancer Research Center Seattle, WA, USA

ruzzo@uw.edu

# Story I

## RNAseq: Bias Correction & Alt Splicing

# "All High-Throughput Technologies are Crap – Initially"

Q. Morris 7-20-2015

# RNA seq



## What we expect: Uniform Sampling



## What we get: highly non-uniform coverage

E.g., assuming uniform, the 8 peaks above 100 are  $\geq$  +10 $\sigma$  above mean





## What we get: highly non-uniform coverage

E.g., assuming uniform, the 8 peaks above 100 are  $\geq$  +10 $\sigma$  above mean



How to make it more uniform?

A: Math tricks like averaging/smoothing (e.g. "coverage") or transformations ("log"), ..., or WE DO

THIS

B:Try to model (aspects of) causation

### The Good News: we can (partially) correct the bias



# Bias is sequence-dependent



### and platform/sample-dependent

Fitting a model of the sequence surrounding read starts lets us predict which positions have more reads.



## Formally...

A reasonable definition of unbiasedness:

 $\Pr(\mathrm{read}\ \mathrm{at}\ \mathfrak{i}) = \Pr(\mathrm{read}\ \mathrm{at}\ \mathfrak{i}|\mathrm{sequence}\ \mathrm{at}\ \mathfrak{i})$ 

From Bayes...

 $\Pr(\mathrm{read} \ \mathrm{at} \ i|\mathrm{sequence} \ \mathrm{at} \ i) = \frac{\Pr(\mathrm{sequence} \ \mathrm{at} \ i|\mathrm{read} \ \mathrm{at} \ i) \Pr(\mathrm{read} \ \mathrm{at} \ i)}{\Pr(\mathrm{sequence} \ \mathrm{at} \ i)}$ 

#### So we might define **bias** as

bias at position  $i = \frac{\Pr(\text{sequence at } i | \text{read at } i)}{\Pr(\text{sequence at } i)}$ 

Want a probability distribution over k-mers,  $k \approx 40$ ?

Some obvious choices:

Full joint distribution: 4<sup>k</sup>-1 parameters

PWM (0-th order Markov): (4-1)•k parameters

Something intermediate:

Directed Bayes network

## Form of the models: Directed Bayes nets



Wetterbom (282 parameters)

One "node" per nucleotide, ±20 bp of read start

- •Filled node means that position is biased
- •Arrow i  $\rightarrow$  j means letter at position i modifies bias at j
- For both, numeric parameters say how much

How–optimize:

 $\ell = \sum \log \Pr[x_i | s_i] = \sum \log \frac{1}{5}$ 



## Result – Increased Uniformity





## "First, do no harm"

Theorem: The probability of "false bias discovery," i.e., of learning a non-empty model from *n* reads sampled from unbiased data, declines *exponentially* with *n*.



Given: r-sided die, with probs  $p_1...p_r$  of each face. Roll it n=10,000 times; observed frequencies =  $q_1, ..., q_r$ , (the MLEs for the unknown  $q_i$ 's). How close is  $p_i$  to  $q_i$ ?

Kullback-Leibler divergence, also known as relative entropy, of Q with respect to P is defined as

$$H(Q||P) = \sum_{i} q_{i} \ln \frac{q_{i}}{p_{i}}$$

where  $q_i(p_i)$  is the probability of observing the i<sup>th</sup> event according to the distribution Q (resp., P), and the summation is taken over all events in the sample space (e.g., all *k*-mers). In some sense, this is a measure of the dissimilarity between the distributions: if  $p_i \approx q_i$  everywhere, their log ratios will be near zero and H will be small; as  $q_i$  and  $p_i$  diverge, their log ratios will deviate from zero and H will increase.

## Fancy name, simple idea: H(Q||P) is just the expected per-sample contribution to log-likelihood ratio test for "was X sampled from $H_0$ : P vs $H_1$ : Q?"

So, assuming the null hypothesis is false, in order for it to be rejected with say, 1000 : 1 odds, one should choose *m* to be inversely proportional to H(Q||P):

$$mH(Q||P) \ge \ln 1000$$
$$m \ge \frac{\ln 1000}{H(Q||P)}$$

Continuing the notation above, suppose *P* as an unknown distribution with parameters  $p_1, \ldots, p_r$ ,  $\sum p_i = 1$  where *r* is the number of points in the sample space (e.g.  $r = 4^k$  in the case of *k*mers). Given a random sample  $X_1, X_2, \ldots, X_r$  of size  $n = \sum_i X_i$  from *P*, it is well known that
the maximum likelihood estimators for the parameters are  $q_i = \frac{X_i}{n} \approx p_i$ . How good an estimate
for *P* is this distribution *Q*? The estimators are unbiased:

$$E[q_i] = E\left[\frac{X_i}{n}\right] = \frac{E[X_i]}{n} = \frac{np_i}{n} = p_i$$

and the standard deviation of each estimate is proportional to  $1/\sqrt{n}$ , so these estimates are increasingly accurate as the sample size increases. A more quantitative assessment of the accuracy of the estimator is obtained by evaluating the KL divergence:

$$H(Q||P) = \sum_{i=1}^{r} q_i \ln \frac{q_i}{p_i} = \sum_{i=1}^{r} q_i \ln \left(1 + \frac{q_i - p_i}{p_i}\right)$$

Using the first two terms of the Taylor series for  $\ln(1 + x)$ , this is

$$H(Q||P) \approx \sum_{i=1}^{r} q_i \left( \frac{q_i - p_i}{p_i} - \frac{1}{2} \left( \frac{q_i - p_i}{p_i} \right)^2 \right)$$
$$= \sum_{i=1}^{r} q_i \frac{q_i - p_i}{p_i} - \frac{q_i}{2p_i} \frac{(q_i - p_i)^2}{p_i}$$

Since  $\sum_{i=1}^{r} q_i = \sum_{i=1}^{r} p_i = 1$ ,  $\sum_{i=1}^{r} p_i \frac{q_i - p_i}{p_i} = 0$ , so

$$H(Q||P) \approx \sum_{i=1}^{r} q_i \frac{q_i - p_i}{p_i} - p_i \frac{q_i - p_i}{p_i} - \frac{q_i}{2p_i} \frac{(q_i - p_i)^2}{p_i}$$
$$= \sum_{i=1}^{r} \frac{(q_i - p_i)^2}{p_i} \left(1 - \frac{q_i}{2p_i}\right)$$
$$\approx \frac{1}{2} \sum_{i=1}^{r} \frac{(q_i - p_i)^2}{p_i}$$

since  $q_i \approx p_i$ . Multiplying by  $n^2/n^2$  we have,

$$H(Q||P) \approx \frac{1}{2n} \sum_{i=1}^{r} \frac{(nq_i - np_i)^2}{np_i}$$
$$= \frac{1}{2n} \sum_{i=1}^{r} \frac{(X_i - E[X_i])^2}{E[X_i]}$$

The summation is the test statistic for the  $\chi^2$  goodness-of-fit test for a multinomial distribution, and as  $n \to \infty$  is known to follow a  $\chi^2$  distribution with r - 1 degrees of freedom. Finally, the expected value of such a random variable is r - 1, hence the expected KL divergence of the MLE inferred distribution Q with respect to the true distribution P is

$$E[H(Q||P)] = \frac{r-1}{2n} \tag{1}$$





#### log2(n)

#### ... while accuracy and runtime rise with *n* (empirically)



*Figure 8:* Median  $R^2$  is plotted against training set size. Each point is additionally labeled with the run time of the training procedure.

Possible objection to the approach:

Typical expts compare gene A in sample I to *itself* in sample 2. Gene A's sequence is unchanged, "so the bias is the same" & correction is useless/dangerous

Responses:

SNPs and/or alternative splicing might have a big effect, if samples are genetically different and/or engender changes in isoform usage

Atypical experiments, e.g., imprinting, allele specific expression, xenografts, ribosome profiling, ChIPseq, RAPseq, ...

Bias is sample-dependent, to an unknown degree

Strong control of "false bias discovery"  $\Rightarrow$  *little risk* 

## Batch Effects? YES!



A: Pairwise proportionality correlation between *technical* replicates; I lane of 2 flowcells each at 5 sites, all HiSeq 2000. B:The absolute change in correlation induced by enabling bias correction (where available). For clarity, BitSeq est. of "MAY 2", excluded; bias correction was extremely detrimental there. 25

#### **BIOINFORMATICS ORIGINAL PAPER**

Vol. 28 no. 7 2012, pages 921–928 doi:10.1093/bioinformatics/bts055

#### Gene expression

#### Advance Access publication January 28, 2012

#### A new approach to bias correction in RNA-Seq

Daniel C. Jones<sup>1,\*</sup>, Walter L. Ruzzo<sup>1,2,3</sup>, Xinxia Peng<sup>4</sup> and Michael G. Katze<sup>4</sup> Department of Computer Science and Engineering, University of Washington, Seattle, WA 98195-2350, <sup>2</sup>Department of Genome Sciences, University of Washington, Seattle, WA 98195-5065, <sup>3</sup>Fred Hutchinson Cancer Research Center, Seattle, WA 98109 and <sup>4</sup>Department of Microbiology, University of Washington, Seattle, WA

Associate Editor: Alex Bateman

#### ABSTRACT

**Motivation:** Quantification of sequence abundance in RNA-Seq experiments is often conflated by protocol-specific sequence bias.

These biases may adversely off

low level not



#### Availability



# Alternate Splicing







Sequencing depth per-isoform is lower

Many reads *ambiguously* mapped to multiple isoforms

Isoform *proportions* and *total expression* may both vary

All the previously-mentioned *bias issues*, including batch effects, affect all measurements

Differences among isoforms may be only a *small fraction* of nucleotides in transcript, potentially exacerbating bias

Isoform annotation is incomplete/poor



Liu, et al. BMC Bioinformatics 15.1 (2014): 364

#### Isolator

Soon to be the world's best isoform quantitation tool

Bayesian hierarchical model + fast MCMC sampler give mean and *uncertainty* in estimates

Can handle dozens of RNAseq samples per hour

When data is lacking, estimates are shrunk towards each other, supressing suprious changes.



1 read vs. 2 reads is probably not a 2-fold change in transcription!

In a nutshell:

A natural assumption is that "nothing has changed," unless refuted by data. (Most genes don't change.)

Hierarchical model allows estimation of baseline expression/isoform usage/variability across *all* samples

This helps compensate for lower per-isoform coverage

Ex: Given 4 isoforms with

- I, I, 2, 2 reads in condition A vs
- 2, 2, 1, 1 reads in condition B
- do you think all 4 are 2x different?

In a nutshell: posterior means are *more stable* than MLEs Likelihood surface max often a broad plateau, not a sharp peak



OTOH, posterior mean is not zero in either case

# Some Benchmarks

"Sequencing Quality Consortium" (SEQC)

4 RNA samples with spike-ins They ran RNAseq They did extensive PCR for "gold standard"

We ran multiple tools (on common alignment) Evaluated "Proportionality correlation" (2•covariance/sum-of-variances, log-scale; usual -1 ... 1 range)

Method	А	В	С	D
Isolator	0.878	0.866	0.839	0.852
Cufflinks	0.870	0.856	0.799	0.841
eXpress	0.870	0.855	0.829	0.840
Salmon	0.866	0.852	0.826	0.836
RSEM/ML	0.865	0.851	0.825	0.835
BitSeg	0.840	0.821	0.802	0.813
Kallisto	0.858	0.840	0.817	0.826
Sailfish	0.844	0.814	0.797	0.802
RSEM/PM	0.840	0.822	0.803	0.811

Table 2: Proportionality correlation between *gene-level* quantification of 18353 genes using PrimePCR <u>qPCR</u> and RNA-Seq quantification.

Method	А	В	С	D
Isolator	0.979	0.978	0.981	0.982
Salmon	0.976	0.975	0.978	0.979
Kallisto	0.972	0.972	0.973	0.976
Sailfish	0.970	0.969	0.969	0.972
Cufflinks	0.967	0.969	0.972	0.974
RSEM/PM	0.943	0.949	0.944	0.949
RSEM/ML	0.941	0.948	0.945	0.951
BitSeg	0.940	0.949	0.943	0.946
eXpress	0.931	0.939	0.935	0.942

Table 3: Proportionality correlation between known proportions of <u>92 ERCC spike-in controls</u> and RNA-Seq quantification.

Method	c vs 0.75a + 0.25b	d vs 0.25a + 0.75b
Isolator	0.975	0.975
BitSeg	0.967	0.967
RSEM/PM	0.968	0.967
Sailfish	0.932	0.925
RSEM/ML	0.922	0.919
Salmon	0.916	0.914
Kallisto	0.907	0.902
eXpress	0.903	0.899
Cufflinks	0.870	0.916

Table 4: Proportionality correlation between <u>transcript-level</u> estimates for the <u>mixed samples</u> C and D and weighted averages of estimates for A and B, corresponding to the mixture proportions for C and D.

Method	Correlation
Isolator	0.919
Kallisto	0.887
Salmon	0.886
RSEM/ML	0.881
Cufflinks	0.881
eXpress	0.825
Sailfish	0.816
RSEM/PM	0.806
BitSeg	0.796

Table 5: Proportionality correlation between ground truth and estimates produced by each method on simulated RNA-Seq.



Figure 2: Proportionality correlation between estimates from <u>4.5 million 300nt MiSeq reads</u> and progressively larger numbers of HiSeq 2000 reads. (100x2)

## Batch Effects? YES!



A: Pairwise proportionality correlation between *technical* replicates; I lane of 2 flowcells each at 5 sites, all HiSeq 2000. B:The absolute change in correlation induced by enabling bias correction (where available). For clarity, BitSeq est. of "MAY 2", excluded; bias correction was extremely detrimental there. 43



Figure 1: Run time needed to process the SEQC data presented in the Results sections. All methods were run a Google Compute Engine instance backed by four Intel Xeon cores and 52GB of a memory.

# Story 2

### Let-7 family of microRNA is required for maturation and adult-like metabolism in stem cell-derived cardiomyocytes

Kavitha T. Kuppusamy<sup>a,b</sup>, Daniel C. Jones<sup>c</sup>, Henrik Sperber<sup>a,b,d</sup>, Anup Madan<sup>e</sup>, Karin A. Fischer<sup>a,b</sup>, Marita L. Rodriguez<sup>f</sup>, Lil Pabon<sup>a,g,h</sup>, Wei-Zhong Zhu<sup>a,g,h</sup>, Nathaniel L. Tulloch<sup>a,g,h</sup>, Xiulan Yang<sup>a,g,h</sup>, Nathan J. Sniadecki<sup>f,i</sup>, Michael A. Laflamme<sup>a,g,h</sup>, Walter L. Ruzzo<sup>c,j,k</sup>, Charles E. Murry<sup>a,g,h,i,l</sup>, and Hannele Ruohola-Baker<sup>a,b,i,j,m,1</sup>

<sup>a</sup>Institute for Stem Cell and Regenerative Medicine, Seattle, WA 98109; Departments of <sup>b</sup>Biochemistry, <sup>c</sup>Computer Science and Engineering, and <sup>d</sup>Chemistry, University of Washington, Seattle, WA 98195; <sup>e</sup>LabCorp Genomic Services, Seattle, WA 98109; <sup>f</sup>Department of Mechanical Engineering, <sup>g</sup>Department of Pathology, <sup>h</sup>Center for Cardiovascular Biology, <sup>i</sup>Department of Bioengineering, and <sup>j</sup>Department of Genome Sciences, University of Washington, Seattle, WA 98195; <sup>k</sup>Fred Hutchinson Cancer Research Center, Seattle, WA 98109; and <sup>I</sup>Department of Medicine/Cardiology and <sup>m</sup>Department of Biology, University of Washington, Seattle, WA 98195

Edited by Eric N. Olson, University of Texas Southwestern Medical Center, Dallas, TX, and approved April 14, 2015 (received for review December 18, 2014)

#### Published: 2015-05-11

PNAS

- It is possible to grow cardiomyocytes (heart muscle cells) from human embryonic stem cells (hESC-CMs)
- Can grow billions of them
- Can transplant them into animals after heart attack
- Cells integrate/heart function improves (after a few weeks)
- BUT arrhythmias, at least in the early stages
- Why? Probably because hESC-CMs were immature.

This will be tried in humans within a few years; ability to lab-culture *mature* hESC-CMs will greatly improve chances for success. Growing them *quickly* will greatly improve the economics. <u>How can we do that?</u>

#### step 1: find molecular biomarkers for maturity



step 1 (cont.): find miRNA biomarkers for maturity, too



#### step2a: let-7 is driver, not passenger – it's necessary





#### step2b: let-7 is driver, not passenger – it's sufficient

#### step3: characterization

#### Pathways

Physiology

Etc.

#### Back to Story 1: differential splicing speaks, too



B: gene expression in cardiac- pathways (E) tracks maturation (unsurprisingly)

C/D: so does splicing (indp of level) via Isolator-detected probable monotonic changes. (Not easily assessed by MLE-based methods...)



RNAseq data shows strong technical biases Of course, compare to appropriate control samples But that's not enough, due to:

batch effects, SNPs/genetic heterogeneity, alt splicing, ...

all of which tend to differently bias sample/control

BUT careful modeling can help.

Alternative splicing changes are very hard to quantify:

lower coverage, ambiguous mapping, bias, ...

BUT careful modeling can help:

Bayesian hierarchical model borrows power across all samples

Sampling/posterior mean estimation is more robust than MLE

Sampling allows novel questions to be addressed, e.g., "is isoform shift probably monotonic in time"

It doesn't have to be slow

AND 90% of genes undergo alt splicing for a reason; you can't see what it is if you don't look

Amazing progress in stem cell technology

Ability to study and control cellular developmental pathways is one of the frontiers of modern biology

Multi-faceted, multi-disciplinary problems with rich data

In this study, microRNA let-7 identified as a key driver of cardiomyocyte maturation

Differential splicing of many transcripts clearly implicated; their exact roles remain to be determined.

# Acknowledgements

## **Daniel Jones**



#### Katze Lab

Michael Katze Xinxia Peng

## Stem Cell Labs

Tony Blau, Chuck Murry, Hannele Ruohola-Baker, Nathan Palpant, Kavitha Kuppusamy, ...

Funding NIGMS, NHGR, NIAID